The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2% of children aged 1-2 years, 52.5% of children aged 3-5 years, 56.7% of children aged 6-9 years, and 90.3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2010.06.059 | DOI Listing |
Virol Sin
December 2024
Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea. Electronic address:
Influenza, a highly contagious respiratory infectious disease caused by an influenza virus, is a threat to public health worldwide. Avian influenza viruses (AIVs) have the potential to cause the next pandemic by crossing the species barrier through mutation of viral genome. Here, we investigated the pathogenicity of AIVs obtained from South Korea and Mongolia during 2018-2019 by measuring viral titers in the lungs and extrapulmonary organs of mouse models.
View Article and Find Full Text PDFMetabolites
December 2024
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
During the COVID-19 pandemic, omics-based methodologies were extensively used to study the pathological mechanisms of SARS-CoV-2 infection and replication in human cells at a large scale [...
View Article and Find Full Text PDFBMC Res Notes
December 2024
Division of Epidemiology and Biostatistics, Monitoring and Evaluation, Wollo University, Dessie, Ethiopia.
Background: HIV/AIDS remains a major public health challenge, in Sub-Saharan Africa (SSA). In 2020, 16% of people living with HIV did not know their HIV status in SSA. Understanding the geospatial distribution of HIV infection, awareness status, and transmission knowledge is crucial for designing effective prevention and control strategies to end the HIV/AIDS pandemic by 2030.
View Article and Find Full Text PDFCancer Med
December 2024
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of California San Diego/Rady Children's Hospital San Diego, San Diego, California, USA.
Background: Measures to control COVID-19 transmission disrupted childhood cancer care. Data on the effects of the COVID-19 pandemic on childhood cancer mortality are lacking. This study describes the impact of the pandemic on childhood cancer early-mortality (≤ 24 months).
View Article and Find Full Text PDFVaccine
December 2024
Department of Preventive Veterinary Medicine, Veterinary School, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address:
In Brazil, at least four lineages of influenza A virus circulate pig population: 2009 H1N1 flu pandemic (pH1N1), human-seasonal origin H3N2, H1N1 and H1N2 (huH1 lineages) viruses. Studies related to the occurrence of swine influenza A virus (SIAV) in Brazilian herds have been detecting an increase of occurrence of huH1 lineages. This study aimed to construct recombinant vaccines against the huH1N1 virus and test the immunogens in a murine model.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!